Your browser doesn't support javascript.
loading
Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson's disease.
Khedher, Laila; Bonny, Jean-Marie; Marques, Ana; Durand, Elodie; Pereira, Bruno; Chupin, Marie; Vidal, Tiphaine; Chassain, Carine; Defebvre, Luc; Carriere, Nicolas; Fraix, Valerie; Moro, Elena; Thobois, Stéphane; Metereau, Elise; Mangone, Graziella; Vidailhet, Marie; Corvol, Jean-Christophe; Lehéricy, Stéphane; Menjot de Champfleur, Nicolas; Geny, Christian; Spampinato, Umberto; Meissner, Wassilios; Frismand, Solène; Schmitt, Emmanuelle; Doé de Maindreville, Anne; Portefaix, Christophe; Remy, Philippe; Fénelon, Gilles; Luc Houeto, Jean; Colin, Olivier; Rascol, Olivier; Peran, Patrice; Durif, Franck.
Afiliación
  • Khedher L; University Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand, France; AgroResonance, INRAE, 2018. Nuclear Magnetic Resonance Facility for Agronomy, Food and Health, doi: 10.15454/1.5572398324758228E12, France. Electronic address: Laila.khedher-brahim@inrae.fr.
  • Bonny JM; AgroResonance, INRAE, 2018. Nuclear Magnetic Resonance Facility for Agronomy, Food and Health, doi: 10.15454/1.5572398324758228E12, France; AgroResonance UR370 QuaPA - INRAE, Saint-Genès-Champanelle 63122, France.
  • Marques A; University Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand, France; Clermont-Ferrand University Hospital, Neurology Department and NS-PARK/FCRIN Network, Clermont-Ferrand, France.
  • Durand E; University Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand, France; Clermont-Ferrand University Hospital, Neurology Department and NS-PARK/FCRIN Network, Clermont-Ferrand, France.
  • Pereira B; Clermont-Ferrand University Hospital, Biostatistics Unit (DRCI), Clermont-Ferrand, France.
  • Chupin M; Sorbonne Université, Institut du Cerveau - ICM, CATI, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, Département de Neurologie and NS-PARK/FCRIN Network, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France.
  • Vidal T; University Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand, France; Clermont-Ferrand University Hospital, Neurology Department and NS-PARK/FCRIN Network, Clermont-Ferrand, France.
  • Chassain C; University Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand, France; Clermont-Ferrand University Hospital, Neurology Department and NS-PARK/FCRIN Network, Clermont-Ferrand, France.
  • Defebvre L; Department of Movement Disorder and NS-PARK/FCRIN Network, Inserm 1172 University of Lille, Lille, France.
  • Carriere N; Department of Movement Disorder and NS-PARK/FCRIN Network, Inserm 1172 University of Lille, Lille, France.
  • Fraix V; Service de Neurologie, CHU de Grenoble and NS-PARK/FCRIN Network, Université Grenoble Alpes, Grenoble Institute of Neuroscience, Grenoble, France.
  • Moro E; Service de Neurologie, CHU de Grenoble and NS-PARK/FCRIN Network, Université Grenoble Alpes, Grenoble Institute of Neuroscience, Grenoble, France.
  • Thobois S; CNRS, Institut des Sciences Cognitives Marc Jeannerod, UMR 5229 CNRS, Lyon, France; Université Claude Bernard, Lyon I, Lyon, France; Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C and NS-PARK/FCRIN Network, Lyon, France.
  • Metereau E; CNRS, Institut des Sciences Cognitives Marc Jeannerod, UMR 5229 CNRS, Lyon, France; Université Claude Bernard, Lyon I, Lyon, France; Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C and NS-PARK/FCRIN Network, Lyon, France.
  • Mangone G; Sorbonne Université, Institut du Cerveau - ICM, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, Département de Neurologie and NS-PARK/FCRIN Network, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France.
  • Vidailhet M; Sorbonne Université, Institut du Cerveau - ICM, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, Département de Neurologie and NS-PARK/FCRIN Network, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France.
  • Corvol JC; Sorbonne Université, Institut du Cerveau - ICM, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, Département de Neurologie and NS-PARK/FCRIN Network, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France.
  • Lehéricy S; Sorbonne Université, Institut du Cerveau - ICM, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, Département de Neurologie and NS-PARK/FCRIN Network, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France.
  • Menjot de Champfleur N; Department of Neuroradiology, Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France; I2FH, Institut d'Imagerie Fonctionnelle Humaine, Hôpital Gui de Chauliac, CHRU de Montpellier, Montpellier, France.
  • Geny C; Department of Geriatrics and NS-PARK/FCRIN Network, Montpellier University Hospital, Montpellier University, Montpellier, France; EuroMov Laboratory, University of Montpellier, 700 Avenue du Pic Saint Loup, Montpellier, Montpellier 34090, France.
  • Spampinato U; Service de Neurologie - Maladies Neurodégénératives and NS-PARK/FCRIN Network, CHU Bordeaux, Bordeaux F-33000, France.
  • Meissner W; Service de Neurologie - Maladies Neurodégénératives and NS-PARK/FCRIN Network, CHU Bordeaux, Bordeaux F-33000, France; Univ. Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, Bordeaux F-33000, France; Dept. Medicine, University of Otago, Christchurch, and New Zealand Brain Research Institute, Christchurch, N
  • Frismand S; Service de Neurologie and NS-PARK/FCRIN Network, CHRU-Nancy, Nancy, France.
  • Schmitt E; Service de Neurologie and NS-PARK/FCRIN Network, CHRU-Nancy, Nancy, France.
  • Doé de Maindreville A; Department of Neurology and NS-PARK/FCRIN Network, Hôpital Maison blanche, Reims, France.
  • Portefaix C; Department of Radiology, Hôpital Maison blanche, Reims, France; CReSTIC Laboratory (EA 3804), University of Reims Champagne-Ardenne, Reims, France.
  • Remy P; Centre Expert Parkinson and NS-PARK/FCRIN Network, CHU Henri Mondor, AP-HP et Equipe Neuropsychologie Interventionnelle, INSERM-IMRB, Faculté de Santé, Université Paris-Est Créteil et Ecole Normale Supérieure Paris Sorbonne Université, Créteil, France.
  • Fénelon G; Centre Expert Parkinson and NS-PARK/FCRIN Network, CHU Henri Mondor, AP-HP et Equipe Neuropsychologie Interventionnelle, INSERM-IMRB, Faculté de Santé, Université Paris-Est Créteil et Ecole Normale Supérieure Paris Sorbonne Université, Créteil, France.
  • Luc Houeto J; INSERM, CHU de Poitiers, Université de Poitiers, Centre d'Investigation Clinique CIC1402, Service de Neurologie and NS-PARK/FCRIN Network, Poitiers, France - CHU - Centre Expert Parkinson de Limoges, Limoges, France.
  • Colin O; INSERM, CHU de Poitiers, Université de Poitiers, Centre d'Investigation Clinique CIC1402, Service de Neurologie and NS-PARK/FCRIN Network, Poitiers, France- CH Brive la Gaillarde, France.
  • Rascol O; Centre d'Investigation Clinique CIC 1436, UMR 1214 TONIC and NS-PARK/FCRIN Network, INSERM, CHU de Toulouse et Université de Toulouse3, Toulouse, France.
  • Peran P; Centre d'Investigation Clinique CIC 1436, UMR 1214 TONIC and NS-PARK/FCRIN Network, INSERM, CHU de Toulouse et Université de Toulouse3, Toulouse, France.
  • Durif F; University Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand, France; Clermont-Ferrand University Hospital, Neurology Department and NS-PARK/FCRIN Network, Clermont-Ferrand, France.
Neuroimage Clin ; 36: 103231, 2022.
Article en En | MEDLINE | ID: mdl-36279753
ABSTRACT
Several postmortem studies have shown iron accumulation in the substantia nigra of Parkinson's disease patients. Iron concentration can be estimated via MRI-R2∗ mapping. To assess the changes in R2∗ occurring in Parkinson's disease patients compared to controls, a multicentre transversal study was carried out on a large cohort of Parkinson's disease patients (n = 163) with matched controls (n = 82). In this study, 44 patients and 11 controls were removed due to motion artefacts, 21 patient and 6 controls to preserve matching. Thus, 98 patients and 65 age and sex-matched healthy subjects were selected with enough image quality. The study was conducted on patients with early to late stage Parkinson's disease. The images were acquired at 3Tesla in 12 clinical centres. R2∗ values were measured in subcortical regions of interest (substantia nigra, red nucleus, striatum, globus pallidus externus and globus pallidus internus) contralateral (dominant side) and ipsilateral (non dominant side) to the most clinically affected hemibody. As the observed inter-subject R2∗ variability was significantly higher than the disease effect, an original strategy (intrasubject subcortical quantitative referencing, ISQR) was developed using the measurement of R2∗ in the red nucleus as an intra-subject reference. R2∗ values significantly increased in Parkinson's disease patients when compared with controls; in the substantia nigra (SN) in the dominant side (D) and in the non dominant side (ND), respectively (PSN_D and PSN_ND < 0.0001). After stratification into four subgroups according to the disease duration, no significant R2∗ difference was found in all regions of interest when comparing Parkinson's disease subgroups. By applying our ISQR strategy, R2(ISQR)∗ values significantly increased in the substantia nigra (PSN_D and PSN_ND < 0.0001) when comparing all Parkinson's disease patients to controls. R2(ISQR)∗ values in the substantia nigra significantly increased with the disease duration (PSN_D = 0.01; PSN_ND = 0.03) as well as the severity of the disease (Hoehn & Yahr scale <2 and ≥ 2, PSN_D = 0.02). Additionally, correlations between R2(ISQR)∗ and clinical features, mainly related to the severity of the disease, were found. Our results support the use of ISQR to reduce variations not directly related to Parkinson's disease, supporting the concept that ISQR strategy is useful for the evaluation of Parkinson's disease.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies Límite: Humans Idioma: En Revista: Neuroimage Clin Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies Límite: Humans Idioma: En Revista: Neuroimage Clin Año: 2022 Tipo del documento: Article